TR201101807T2 - Rosuvastatin kalsiyumun farmasotik bileşimleri - Google Patents

Rosuvastatin kalsiyumun farmasotik bileşimleri

Info

Publication number
TR201101807T2
TR201101807T2 TR2011/01807T TR201101807T TR201101807T2 TR 201101807 T2 TR201101807 T2 TR 201101807T2 TR 2011/01807 T TR2011/01807 T TR 2011/01807T TR 201101807 T TR201101807 T TR 201101807T TR 201101807 T2 TR201101807 T2 TR 201101807T2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
rosuvastatin calcium
rosuvastatin
sodium carbonate
anhydrous sodium
Prior art date
Application number
TR2011/01807T
Other languages
English (en)
Inventor
Far�� Ferhat
Apar� Serdar
Avci Recep
Original Assignee
Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ filed Critical Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Publication of TR201101807T2 publication Critical patent/TR201101807T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş, rosuvastatinin veya farmasötik olarak kabul edilebilir tuzlarının; ağırlıkça %0.5 ile %2 oranında olması gereken susuz sodyum karbonat kullanımının sağlandığı, 0.1 N HCl ortamında dissolüsyon profilleri üzerine etkisi olan, özellikle rosuvastatinin kalsiyum tuzu ile susuz sodyum karbonat tuzunun farmasötik bileşimleri ile ilgilidir.
TR2011/01807T 2008-06-27 2008-06-27 Rosuvastatin kalsiyumun farmasotik bileşimleri TR201101807T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/052595 WO2009156796A1 (en) 2008-06-27 2008-06-27 Pharmaceutical compositions of rosuvastatin calcium

Publications (1)

Publication Number Publication Date
TR201101807T2 true TR201101807T2 (tr) 2012-02-21

Family

ID=40386506

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/01807T TR201101807T2 (tr) 2008-06-27 2008-06-27 Rosuvastatin kalsiyumun farmasotik bileşimleri

Country Status (19)

Country Link
US (1) US20110098315A1 (tr)
EP (1) EP2306982B1 (tr)
JP (1) JP2011525901A (tr)
KR (1) KR101283147B1 (tr)
AU (1) AU2008358622A1 (tr)
BR (1) BRPI0822782A2 (tr)
CA (1) CA2728539A1 (tr)
DK (1) DK2306982T3 (tr)
EA (1) EA201170101A1 (tr)
ES (1) ES2535106T3 (tr)
GE (1) GEP20135735B (tr)
IL (1) IL210102A0 (tr)
MA (1) MA32498B1 (tr)
MX (1) MX2010013834A (tr)
PT (1) PT2306982E (tr)
TN (1) TN2010000585A1 (tr)
TR (1) TR201101807T2 (tr)
WO (1) WO2009156796A1 (tr)
ZA (1) ZA201009057B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609138B2 (en) * 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
RO129060B1 (ro) * 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN107072997A (zh) 2014-11-11 2017-08-18 盐野义制药株式会社 含有对光不稳定的药物的多层片剂
JP6108635B2 (ja) * 2015-05-14 2017-04-05 ダイト株式会社 ロスバスタチン含有口腔内速崩壊錠
HRP20251674T1 (hr) 2019-07-31 2026-02-13 Intas Pharmaceuticals Ltd. Farmaceutski pripravak koji sadrži inhibitore hmg coa reduktaze i fenofibrat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Ｈｄｌを高める併用療法用複合物
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
WO2008005543A2 (en) * 2006-07-06 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions with controlled pharmacokinetics
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof

Also Published As

Publication number Publication date
IL210102A0 (en) 2011-02-28
ZA201009057B (en) 2012-01-25
BRPI0822782A2 (pt) 2015-09-29
TN2010000585A1 (en) 2012-05-24
PT2306982E (pt) 2015-05-18
KR20110027711A (ko) 2011-03-16
CA2728539A1 (en) 2009-12-30
WO2009156796A1 (en) 2009-12-30
JP2011525901A (ja) 2011-09-29
GEP20135735B (en) 2013-01-25
EP2306982B1 (en) 2015-01-07
AU2008358622A1 (en) 2009-12-30
ES2535106T3 (es) 2015-05-05
MA32498B1 (fr) 2011-07-03
KR101283147B1 (ko) 2013-07-05
DK2306982T3 (en) 2015-04-20
MX2010013834A (es) 2011-02-21
EA201170101A1 (ru) 2011-08-30
US20110098315A1 (en) 2011-04-28
EP2306982A1 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
TR201101807T2 (tr) Rosuvastatin kalsiyumun farmasotik bileşimleri
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
EA201070786A1 (ru) Бензофуропиримидиноны
IN2012DN01233A (tr)
MX2010004576A (es) Derivados de pirimidina novedosos.
UA105229C2 (uk) Фармацевтичний склад
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
EA201101301A1 (ru) Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
CR20110209A (es) Composición farmacéutica sólida
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
EA201290229A1 (ru) Производные спиролактама и их применение
AR063027A1 (es) Derivados de sulfonamida
CY1111914T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
AR088398A1 (es) Preparacion de liberacion sostenida
CR10410A (es) Carboxamidas sustituidas.
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TW200833342A (en) 2-substituted pyrimidines I in therapy
EA201100502A1 (ru) Гликозидные производные и их применения